Get the Stockscreener App
6.59
1.49%
-0.10
After Hours:
6.47
-0.12
-1.82%
Scisparc Ltd stock is traded at $6.59, with a volume of 9,168.
It is down -1.49% in the last 24 hours and up +54.33% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$6.69
Open:
$6.6
24h Volume:
9,168
Relative Volume:
0.01
Market Cap:
$3.78M
Revenue:
$856.00K
Net Income/Loss:
$-12.56M
P/E Ratio:
-0.0285
EPS:
-231.4926
Net Cash Flow:
$-4.14M
1W Performance:
-4.91%
1M Performance:
+54.33%
6M Performance:
+22.77%
1Y Performance:
-85.09%
1-Day Range:
$6.47
$6.7775
1-Week Range:
$5.86
$7.06
52-Week Range:
$2.98
$80.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
6.59 | 3.78M | 856.00K | -12.56M | -4.14M | -231.49 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. (SPRC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement - NewMediaWire
NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement - TheNewswire
SciSparc Ltd. (SPRC) stock price, news, quote and history - Yahoo Finance UK
SciSparc Subsidiary NeuroThera Wins Japanese Patent for Novel Pain and Fever Therapy - TipRanks
SciSparc Ltd. (Nasdaq: SPRC) subsidiary gains Japanese patent on novel pain treatment combo - Stock Titan
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - The Manila Times
SciSparc Subsidiary NeuroThera Receives Japanese Patent for 4-Aminophenol Combination Therapy - quiverquant.com
Japanese patent covers SciSparc subsidiary’s pain and fever combo - Stock Titan
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - tradingview.com
SPRC Stock Price, Quote & Chart - ChartMill
Scisparc Ltd (SPRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scisparc Ltd (SPRC) Stock News Today - TradingKey
SciSparc’s NeuroThera Launches Phase IIb Tourette Trial at Yale Child Study Center - TipRanks
SciSparc (Nasdaq: SPRC) launches Phase IIb SCI-110 Tourette study - Stock Titan
SciSparc’s NeuroThera Opens Yale Site for Phase IIb SCI-110 Tourette Syndrome Trial - quiverquant.com
Tourette drug candidate enters Phase IIb with prior 21% tic reduction - Stock Titan
Price to book forward of SciSparc Ltd. – NASDAQ:SPRC - TradingView
SciSparc Announces NeuroThera Labs Achieves Milestone in Quantum-Enabled Clinical Trial Data Analytics Platform - quiverquant.com
What's Going On With SciSparc Shares On Friday? - Benzinga
SciSparc (SPRC) Drops 4.29% as Shares Test Key Support Near $8.26Retail Sentiment - dars.gov.et
Enterprise value to EBIT forward of SciSparc Ltd. – NASDAQ:SPRC - TradingView
SciSparc (SPRC) Surges Over 70%: Analyzing the Massive RallyHigh Volume Stocks - dars.gov.et
SciSparc Moves Into Agentic AI With New Scientific Advisory Board - TipRanks
Scisparc Ltd. Announces Establishment of Scientific Advisory Board - marketscreener.com
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Scisparc Ltd (SPRC) Earnings Date & Reports & Earnings News - TradingKey
Scisparc Ltd (SPRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SciSparc shifts focus to agentic AI market - Investing.com
Scisparc Ltd (SPRC) Balance Sheet - TradingKey
Scisparc Ltd (SPRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scisparc Ltd (SPRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scisparc Ltd (SPRC) Institutional Confidence - TradingKey
SciSparc shifts focus to agentic AI market By Investing.com - Investing.com Canada
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity - The Manila Times
SciSparc targets agentic AI market and forms ad... - Pluang
Scisparc Ltd (SPRC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SciSparc Ltd. Targets Agentic AI Market and Plans Scientific Advisory Board for AI and Cybersecurity - Quiver Quantitative
SciSparc Announces Decision to Target the Agentic AI - GlobeNewswire
Scisparc Ltd (SPRC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scisparc Ltd (SPRC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SciSparc Ltd. Revenue Breakdown – NASDAQ:SPRC - TradingView
SPRC|Scisparc Ltd|Price:5.330|Chg%:-0.390 - TradingKey
SciSparc Company Profile & Introduction - Moomoo
Scisparc Ltd (SPRC) Income Statement - TradingKey
SciSparc (SPRC) Stock Forecast & Analyst Ratings - Moomoo
SciSparc(SPRC) Stock Options Chain | Quotes & News - Moomoo
SciSparc Ltd. (Nasdaq: SPRC) starts Phase IIb SCI-110 trial for Tourette - Stock Titan
NeuroThera starts Phase IIb trial in Germany fo... - Pluang
SciSparc Subsidiary NeuroThera Initiates Phase IIb SCI-110 Clinical Trial Site at Hannover Medical School for Adult Tourette Syndrome - Quiver Quantitative
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):